-
EXPLORING BARRIERS TO SHARED DECISION-MAKING (SDM) IN RARE DISEASES FROM THE PHYSICIAN PERSPECTIVE IN EUROPE: FINDINGS FROM A CROSS-SECTIONAL SURVEY
Aug 11, 2026, 17:16 PM -
SURVIVAL CURVE RECONSTRUCTION AS A VALIDATED FRAMEWORK FOR MODEL-BASED COST-UTILITY ANALYSIS IN HTA: A REPRODUCIBLE APPROACH USING PUBLICLY AVAILABLE TRIAL DATA
Aug 11, 2026, 17:16 PM -
UPTAKE OF FLT3 INHIBITORS AND IMPACT ON OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN SWEDEN
Aug 11, 2026, 17:16 PM -
THE ECONOMIC BURDEN OF EARLY-STAGE HR+/HER2- BREAST CANCER (BC) IN SPAIN: A COST-OF-ILLNESS STUDY
Aug 11, 2026, 17:16 PM -
EMA VS FDA APPROVALS OF INNOVATIVE MEDICINES: A SYSTEMATIC ANALYSIS OF APPROVAL EXCLUSIVITY, APPROVAL SEQUENCING, REGULATORY TIMELINES (2021-2026)
Aug 11, 2026, 17:16 PM -
A SCENARIO-BASED ASSESSMENT OF THE EFFECTS OF PROPOSED US INTERNATIONAL REFERENCE PRICING MODELS FOR MEDICARE AND MEDICAID
Aug 11, 2026, 17:16 PM -
HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH RARE MOLD INFECTIONS: EQ-5D-5L RESULTS FROM A PHASE IIB TRIAL EVALUATING OLOROFIM IN ADULTS WITH INVASIVE FUNGAL INFECTIONS AND LIMITED OR NO TREATMENT OPTIONS
Aug 11, 2026, 17:16 PM -
ESTIMATION OF THE ECONOMIC BURDEN IN TRAINING HOSPITAL PERSONNEL FOR INTRAUTERINE DEVICE APPLICATION USING A MONTE CARLO MATHEMATICAL MODEL
Aug 11, 2026, 17:16 PM -
GLOBAL LANDSCAPE OF FISCAL HEALTH MODELING FOR IMMUNIZATION: A TARGETED LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
INDIRECT TREATMENT COMPARISONS IN BREAST CANCER: METHODS AND ACCEPTANCE IN NICE SUBMISSIONS
Aug 11, 2026, 17:16 PM -
TARGETED LITERATURE REVIEW OF DIAGNOSIS, SCREENING AND HEALTH-ECONOMIC MODELS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Aug 11, 2026, 17:16 PM -
REAL-TERMS DEPRECIATION OF WILLINGNESS-TO-PAY THRESHOLDS FOR DOUBLE-BRANDED ONCOLOGY COMBINATIONS ACROSS HTA MARKETS, 2015-2025
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ANALYSIS OF SINGLE-DOSE PCV20 VERSUS PCV13 FOLLOWED BY PPV23 IN THE ALGERIAN ADULT POPULATION
Aug 11, 2026, 17:16 PM -
ENVIRONMENTAL IMPACT OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: A CARBON FOOTPRINT ANALYSIS IN FRANCE
Aug 11, 2026, 17:16 PM -
NHS OUTSOURCING COST IMPLICATIONS OF AN AI-PRIORITISED WORKFLOW FOR REPORTING HEAD CT IN EMERGENCY CARE
Aug 11, 2026, 17:16 PM -
A MATHEMATICAL APPRAISAL OF THE FAMILY AND CAREGIVING EFFECTS FRAMEWORK IN MODELING CAREGIVER SPILLOVER EFFECTS
Aug 11, 2026, 17:16 PM -
MATCHING-ADJUSTED INDIRECT COMPARISONS OF NIVOLUMAB + IPILIMUMAB VS DURVALUMAB + TREMELIMUMAB FOR FIRST-LINE UNRESECTABLE HEPATOCELLULAR CARCINOMA: ASIAN SUBGROUP RESULTS
Aug 11, 2026, 17:16 PM -
SYSTEMATIC LITERATURE REVIEW ON THE PERFORMANCE OF DYNAMIC TRANSMISSION MODELS IN PNEUMOCOCCAL DISEASE
Aug 11, 2026, 17:16 PM -
CLINICAL REMISSION IN TYPE 1 DIABETES: A CONCEPTUAL MODEL OF IMMUNOMETABOLIC RECOVERY, C-PEPTIDE PRESERVATION, AND BENEFICIAL CLINICAL EFFECTS
Aug 11, 2026, 17:16 PM -
RECOGNITION OF TARGET TRIAL EMULATION AND THE ESTIMAND FRAMEWORK IN REGULATORY AND HTA GUIDANCE: A EUROPEAN AND NORTH AMERICAN LANDSCAPE REVIEW
Aug 11, 2026, 17:16 PM
